Bioprocessing technology is developing rapidly due to the automation of data collection and processing. But as Richard Owen (Head of Biology) and Arianna Rech (Bioprocessing Lead) explain, there is more that needs to be done to keep up with industry demand.
In the fourth of our GenAI series, we’ve prompted the LLM to give us insights. So for the Chatbot’s perspective, here is the response from GPT-4 - verbatim.
In our third article of the series, we explore how data scientists can extract valuable insights and drive innovation using GenAI and LLMs.
In the second installment of our series, we delve deeper into how product owners can harness the power of GenAI and LLMs to dramatically accelerate innovation.
GenAI has the potential to dramatically accelerate innovation, but how? In this article, we discuss how to leverage GenAI and LLMs by drawing from our experience implementing GenAI into business'.
Steve Augustyn, our Deputy Head of Drug Delivery reflects on key themes for respiratory therapy
Karla Sanchez explores the rapidly evolving field of dementia care, examining both the current landscape and emerging technologies that empower patients to stay independent for longer.
Discover how healthcare innovation can bridge the nursing knowledge gap in wound, ostomy, and continence care, from the perspective of Erik Andersen, an Insights Research Associate at CDP and practicing ICU nurse.
Pace is accelerating for tackling neurodegenerative diseases. In this article, Biomedical Engineers Alejandra and Karla focus on two areas of progress: how treatments have moved on and hope for the future.
Therapeutic oligonucleotides are a promising therapy for future applications. Here, biomedical engineers, Alejandra and Carla, discuss the challenges that need to be addressed to unlock large-scale oligonucleotide manufacturing.
As we develop in scale, facilities and capabilities, we’re acutely aware of the risk that our environmental impact grows in step - and it’s something we feel a strong duty to minimize.
Fresh from 'Drug Delivery to the Lungs' conference in Edinburgh, Mark Allen shares his insights on the major themes from the event and a trend set to reshape the future of respiratory drug delivery.